Table 1.

Meta-analysis of the 1p13.3, rs599839 association with AAA

rs599839 A>G, 1p13.3	Controls, n	Cases, n	MAF controls	MAF cases	OR (95% CI)	P-value
NZ discovery	612	608	0.249	0.180	0.66 (0.54–0.81)	3.3 × 10−5
NZ validation	1766	713	0.240	0.191	0.75 (0.64–0.88)	2.4 × 10−4
WTCCC	5605	1286	0.232	0.202	0.84 (0.75–0.93)	8.9 × 10−4
Iceland	61 639	1163	0.209	0.176	0.81 (0.72–0.91)	0.006
The Netherlands	2792	840	0.229	0.228	0.99 (0.45–2.17)	0.98
Western Australia	373	377	0.211	0.185	0.85 (0.66–1.10)	0.21
Leeds, UK	456	684	0.238	0.197	0.79 (0.64–0.96)	0.02
Pennsylvania, USA	1313	773	0.222	0.193	0.84 (0.72–0.99)	0.03
Mayo eMERGE cohort, USA	1000	230	0.226	0.209	0.89 (0.69, 1.14)	0.36
Belgium	267	176	0.190	0.181	0.94 (0.65–1.35)	0.74
Canada	153	198	0.260	0.214	0.77 (0.51–1.16)	0.21
Combined	75 976	7048			0.81 (0.76–0.85)	7.2 × 10−14

The rs599839 G allele was associated with reduced AAA risk in 6 of the 11 cohorts (P-value for heterogeneity 0.68)